The rocky road to personalized medicine in acute myeloid leukaemia.

about

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update FOXM1 contributes to treatment failure in acute myeloid leukemia

P2860

Q56378380-25F8FDB8-DF87-47FD-BAD2-C174DDAEFC5A Q58792314-01812C8C-E230-48CB-BFF3-EC6D28D6F565

P2860

The rocky road to personalized medicine in acute myeloid leukaemia.

Item

http://www.wikidata.org/entity/Q47561008

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

The rocky road to personalized medicine in acute myeloid leukaemia.

@en

The rocky road to personalized medicine in acute myeloid leukaemia.

@nl

type

Item

label

The rocky road to personalized medicine in acute myeloid leukaemia.

@en

The rocky road to personalized medicine in acute myeloid leukaemia.

@nl

prefLabel

The rocky road to personalized medicine in acute myeloid leukaemia.

@en

The rocky road to personalized medicine in acute myeloid leukaemia.

@nl

P1476

The rocky road to personalized medicine in acute myeloid leukaemia

@en

P2093

Brian Parkin

http://www.w3.org/2001/XMLSchema#string

Bryan Brinda

http://www.w3.org/2001/XMLSchema#string

Irum Khan

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Novel immunotherapies in lymphoid malignancies

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Implications of NRAS mutations in AML: a study of 2502 patients.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

P304

1411-1427

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCMM.13478

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Heiko Konig

P577

2018-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29327808

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

5824388

http://www.w3.org/2001/XMLSchema#string

The rocky road to personalized medicine in acute myeloid leukaemia.

about

P2860

P2860

The rocky road to personalized medicine in acute myeloid leukaemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932